Fig. 18
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(C-E) derived from the model simulation
Fig. 18 | Orphanet Journal of Rare Diseases
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(C-E) derived from the model simulation
Orphanet Journal of Rare Diseases